5:58 PM
 | 
Sep 06, 2013
 |  BC Extra  |  Top Story

FDA approves Abraxane for pancreatic cancer

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) to expand the label of Abraxane nab-paclitaxel to include first-line treatment of advanced pancreatic cancer in combination with gemcitabine. The label includes a claim of...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >